Effectiveness of Dapagliflozin + Saxagliptin to revert from a standard basalbolus insulin treatment (BBIT) regimen to a basal supported oral therapy (BOT) in patients with Type 2 Diabetes &NDASH; a randomised double-blinded study &NDASH; a randomised double-blinded study

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 28 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapagliflozin (Primary) ; Saxagliptin (Primary) ; Insulin
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms DapaSaxaBBIT

Most Recent Events

07 Feb 2020 Status changed from recruiting to completed.
07 Feb 2020 Status changed from completed to discontinued.
17 May 2018 Planned End Date changed from 1 Feb 2018 to 1 Jun 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight